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Background
Determining correlates of protection for Ebola vaccines has proved difficult and ambiguous [1] . Anti-Ebola antibodies possess strong neutralising capacity [2, 3] , moreover, antibodies with limited neutralising activity were protective in animal models and human in vitro culture systems suggesting that neutralisation alone presents an incomplete mechanistic picture of in vivo protection [3] [4] [5] . Ebola-specific antibodies induce antibody-dependent cellular cytotoxicity (ADCC) in human peripheral blood NK cells and NK cell lines in vitro; in light of this, Fcmediated function in anti-Ebola monoclonal antibody (mAb) therapy and vaccine-induced protection is gaining in interest [5] [6] [7] . Analysis of the primary response to the candidate Ebola vaccine, rVSV-ZEBOV, revealed a correlation between early NK cell activation and anti-Ebola antibody titre [8] . Also, protection of non-human primates against Ebola virus challenge is associated with a low IgG2:IgG1 antibody isotype ratio, compatible with ADCC as a major mechanism of protection [9] . In murine experimental filovirus vaccines, induction of antiglycoprotein (GP) antibodies with robust ADCC function was critical for protection [10] [11] [12] .
Taken together, these studies suggest Fc functions of anti-Ebola antibodies potentially contribute to protection and may be exploited for improving vaccine and therapeutic mAb efficacy and as markers of vaccine-induced immunity.
NK cells, like other innate immune effector cells, express Fc receptors (FcR) on their surface
allowing activation of cell-mediated antibody-dependent anti-viral functions [13] . Antibodydependent phagocytosis (ADP) of virus or virally-infected cells by monocytes, macrophages and neutrophils, and ADCC mediated by NK cells, promote the clearance of infected cells, reducing viral load and dissemination. NK cell ADCC is principally mediated by crosslinking of FcγRIIIa (CD16) by the Fc region of immunoglobulinssubclasses IgG1 and IgG3 in humans which leads to phosphorylation of immunoreceptor tyrosine-based activation motifs (ITAM) and downstream pathway activation. Killing proceeds by the release of lytic granules from activated NK cells inducing apoptosis of virally infected cells. Cross-linking of CD16 by antibody induces its cleavage from the NK cell surface [14] [15] [16] , despite this, NK cells can move A c c e p t e d M a n u s c r i p t 5 on to kill multiple targets providing effective clearance of infected cells [17] . Fc functions of broadly neutralising antibodies have been shown to be indispensable for protection against influenza virus infection [18, 19] , however, the role of Ebola vaccine induced antibodydependent NK cell functions is unknown.
The novel Ad26.ZEBOV, MVA-BN-Filo 2-dose vaccine regimen has shown promising results in phase 1 and 2 studies; high levels of anti-Ebola GP specific antibody are sustained for at least 360 days with high neutralising activity and a strong correlation between binding and neutralising antibody responses [20] [21] [22] [23] . However, vaccine regimens based on Ad26.ZEBOV and MVA-BN-Filo differing in order and interval between dose 1 and dose 2 induce substantially different serum antibody concentrations in U.K. based volunteers at both postdose 1 and post-dose 2 time points [21] . Therefore, the purpose of this study was to assess the ability of post-Ad26.ZEBOV, MVA-BN-Filo vaccination sera (of differing regimen) to mediate antibody-dependent NK cell function in an in vitro ADCC assay targeting immobilised Ebola virus GP (EBOV GP). We observe robust, antibody-dependent activation of NK cells in whole human peripheral blood mononuclear cell (PBMC) preparations cultured with EBOV GP in the presence post-Ad26.ZEBOV, MVA-BN-Filo vaccination serum. NK cell activation varied depending on vaccine regimen and correlated positively with antibody concentration. NK activity also varied between NK cell donors, consistent with differentiation phenotype influencing the potency of antibody-dependent NK cell responses.
Methods

Study participants and samples
Eligible, healthy volunteers were recruited to take part in the EBL1001 (EBOVAC consortium) single-centre, randomised, placebo-controlled, observer blind Ebola vaccine trial held in Oxford, U.K. (ClinicalTrials.gov Identifier: NCT02313077). A further 15 volunteers were subsequently recruited for group 5, see Milligan et al. for additional methodology [21] . Serum samples from 72 donors (age range 18-50 years) were obtained for this study from nonplacebo arms (Table 1) . Additional blood samples were obtained from non-vaccinated, non-study volunteers. PBMC were isolated using Histopaque 1077 (Sigma-Aldrich, U.S.A) gradient centrifugation and cryopreserved in liquid nitrogen or used immediately. Ebola GP-specific IgG concentration and Ebola GP-specific pseudovirion virus neutralising antibody titres (psVNA) were determined previously [21] and human cytomegalovirus (HCMV) serostatus was determined by IgG ELISA (Demeditec, Kassel, Germany), 36% HCMV seropositive. The trial protocol and study documents were approved by the National Research Ethics Service (reference number 14/SC/1408) and the LSHTM Research Ethics Committee (reference number 14383). 
In vitro culture assays
Flow cytometry
Cells were stained in 96-well round-bottom plates as described previously [24] . Briefly, cells were blocked with Fc Receptor (FcR) Blocking Reagent (Miltenyi Biotech, Germany) and stained with fluorophore labelled antibodies for surface markers including viability marker (Fixable Viability Stain 700; BD Biosciences) in FACS buffer. Cells were washed in FACS buffer, fixed and permeabilised using Cytofix/Cytoperm Kit (BD Biosciences). Cells were then stained for intracellular markers with further FcR blocking, washed again and resuspended in FACS buffer and acquired using a BD LSRII flow cytometer using FACSDiva software and analysed using FlowJo V10 (Tree Star, Oregon, U.S.A). FACS gates were set using unstimulated cells or FMO controls, a minimum cut off was determined as the frequency of responding NK cells in the presence of FCS alone [21] , samples with less than 100 NK cell events were excluded from the analysis.
Fluorophore-labelled antibodies used were: anti-CD3-V500 (clone UCHT1) (BD Biosciences), anti-CD56-BV605 (clone HCD56) and anti-IFN-γ-BV785 (clone 45.B3) (Biolegend, London, U.K.), anti-CD16-APC (clone CB16), anti-CD57-e450 (clone TB01) (eBiosciences) and anti-NKG2C-PE (clone 134591) (R&D systems). Cells were acquired using FACSDiva software, data were analysed using FlowJo V10 (Tree Star, Oregon, U.S.A). 
Results
Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine induced antibody-dependent NK cell activation in vitro.
To Variation in NK cell function according to vaccine regimen is consistent with data on the effect of vaccine regimen on anti-GP antibody concentration [21] . Therefore, we next analysed the relationship between individual Ebola GP-specific IgG concentration (determined by Milligan et al. previously [21] ) and antibody-dependent NK cell activation. With all groups combined, there was a significant positive correlation between post-dose 2 antibody concentration and frequencies of NK cell CD107a and IFN-γ and a negative correlation with CD16 MFI (Figure   4a ). Table   2 ). Antibody concentration and NK cell function also correlated significantly after dose 1 when all groups were combined ( Supplementary Figure 3a-c) , however, this relationship was only significant for group 3 (Ad26.ZEBOV followed by MVA-BN-Filo at day 29) when analysed separately ( Table 2 ). There was no correlation between antibody concentration and antibodydependent NK cell function at post-dose 1 and post-dose 2 in MVA-BN-Filo followed by Ad26.ZEBOV vaccinated individuals (groups 1 and 2) ( Table 2) . Therefore, in vaccine regimen inducing the highest post-dose 2 responses (groups 1 and 2), the association between the two variables is lost.
Analysis of antibody-dependent NK cell responses and Ebola GP-specific pseudovirion virus
neutralising antibody titres (psVNA) titres revealed a significant positive correlation across the entire cohort with the frequency of NK cell IFN-γ and a negative correlation with CD16 expression, although no association was observed with CD107a expression (Figure 4b) .
Consistent with the association with anti-GP antibody concentration, we observed the strongest correlations between all NK cell functions and psVNA titres for groups 3 and 4 (Ad26.ZEBOV followed by MVA-BN-Filo) ( Table 3) . (Figure 5b) . Overall, NK cell CD107a expression was apparent in all NK cell subsets, as was CD16 downregulation ( Figure   5c ). IFN-γ was significantly upregulated with post-dose 2 serum in CD56 dim CD57and CD56 dim CD57 + NKG2Csubsets with the highest frequency of IFN-γ expression observed within the CD56 dim NK cell subsets (Figure 5c ). Almost half (41.0%) of total NK cell IFN-γ production was attributed to CD56 dim CD57 + NK cells (Figure 5d ). These data demonstrate that differences in NK cell differentiation status introduce additional inter-donor variation in NK cell ADCC responses.
Discussion
We have shown that antibodies to the Ebola virus GP induced by the Ad26.ZEBOV, MVA-BN- [20, 22] .
Our data highlight substantial variation in frequencies of activated NK cells subsets both within a single donor and between donors in response to post-vaccination antibody. Many variables effect NK cell ADCC function including FcR polymorphisms [25] , antibody glycosylation [26] and cytokine mediated regulation [27] . Antibody binding epitopes can also affect the ADCC function of vaccine induced antibodies [3] -neutralising antibodies bind Ebola GP core epitopes potentially inhibiting virion cell entry whereas antibodies with Fc function bind epitopes on the exposed upper domains of GP presented on the surface of infected cells [6, 28] . Ebola GP returning to the surface of the infected cell and liberation of soluble GP for immune complex formation could promote NK cell ADCC. However, GP shed from infected cells can also bind anti-GP antibodies and block, rather than facilitate their activity [29] .
HCMV has seropositivity rates of up to 60% in adults in developed countries and near universal in developing countries [30] . HCMV infection strongly influences NK cell function in response to viral antigens and promotes accumulation of NK cells expressing NKG2C with a mature (CD56 dim CD57 + ) and 'adaptive' (FcεRγ -) phenotype [31] [32] [33] with enhanced IFN-γ secretion in response to antibody-coated targets [34] [35] [36] . HCMV serostatus may impact antibody-dependent NK cell activation after Ad26.ZEBOV, MVA-BN-Filo regimen vaccination, therefore, measuring NK cell function may help evaluate vaccine responses across different human populations.
Future use of CD16 expressing or transfected NK cell lines for standardisation of these assays could potentially enable comparison across multiple vaccine studies [37] . However, NK cell tumour lines such as NK-92, are largely derived from pre-NK cells and do not reflect the range A c c e p t e d M a n u s c r i p t 23 The NK cell CD107a, CD16 and IFN-γ responses were also analysed according to NK cell differentiation subset (c) and the proportion of total NK cell IFN-γ expression (at post-dose 2) attributed to each subset is shown as a pie graph with each slice representing the median (d).
Graphs show before and after plots with a line connecting each donor or one dot per donor with a line representing the median. Comparisons between pre and post-vaccination serum responses were performed using Wilcoxon signed-rank test and between subsets using one-
